The CSU indication is the seventh disease driven in part by underlying type 2 inflammation in which Dupixent has received approval.

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

Penmenvy combines the antigenic components of Bexsero (meningococcal Group B vaccine) and Menveo (meningococcal Groups A, C, Y, and W-135 oligosaccharide diphtheria CRM197 conjugate vaccine).

Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

The updated recommendations are pending final approval by the director of the CDC and the Department of Health and Human Services.

HealthDay News — Two widely consumed food additive mixtures may increase type 2 diabetes incidence, according to a study published online April 8 in PLOS Medicine.

Pfizer ends danuglipron clinical program for obesity; FDA warns about counterfeit Ozempic; daily pill shows promise in reducing HbA1c; mavacamten misses in nonobstructive HCM trial and the FDA clears ...

Proposal includes steps that need to be taken to strengthen preparedness, readiness, and health system functions and resilience.